Medical Field: Gastroenterology
Award: Winner
Country: Slovenia
Year: 2019
Research Work: Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease
Published in: Alimentary Pharmacology & Therapeutics

David Drobne, MD, PhD, from the Department of Gastroenterology of the University Medical Centre Ljubljana, together with his colleagues discovered a technology which enables adaptation of doses and concentration of medicine for every patient with a chronic inflammatory bowel disease. This technology ensures the patients a safer treatment, and its added value is also excellent price efficacy, which makes it more accessible to less developed countries as well.

Research is the way to improve patient care in the long term. For this reason the International Medis Awards represent a recognition for our group that our attempts matter. Not only to us, who are constantly involved in everyday patient care, but also to the broader community.